Esperto Medical, a health technology startup focused on critical care and remote patient monitoring, has announced the successful close of an oversubscribed Series A investment round. The round was co-led by Catalyst Health Ventures and Bold Capital Partners, with additional support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures.
The funding will be used to support the productization and clinical testing of Esperto’s groundbreaking Resonance Sonomanometry (RSM) technology. RSM utilizes sound waves at different frequencies to measure blood pressure directly within arteries, offering a potentially more accurate and user-friendly approach than existing methods. A key advantage of RSM is that it requires no calibration, simplifying setup and use. The technical details of the technology are available in the journal PNAS Nexus.
Several key figures involved in the funding round and the company itself shared their enthusiasm for the technology and its potential:
“RSM’s flexibility to work all over the body – on the arms, legs, even the neck – allows it to accommodate a wide range of patients. It has the potential to enhance cardiovascular monitoring for everyone.” – Cofounder and Chief Medical Officer, Alaina Rajagopal, MD, PhD
“RSM is a truly new monitoring technology and has significant competitive advantages. I am excited for its application not just in the hospital setting but in personal use, as well.” – Joshua Phillips, co-founder and Managing Partner of Catalyst Health Ventures (joining the board)
“I have had the chance to track this technology from early days at Caltech. Esperto has built a great team to bring RSM to the clinic and beyond. I look forward to helping them continue their rapid progress toward transforming patient monitoring across hospital settings.” – Helen McBride, PhD, Partner at Bold Capital Partners (joining the board)
“We are pleased to welcome CHV, Bold Capital Partners and others to Esperto as we work to advance RSM for the benefit of patients, providers, health care systems, and payors. We are thrilled to have the chance to bring forward a solution to a longstanding clinical problem: accurate, noninvasive, calibration-free, continuous blood pressure monitoring.” – Aditya Rajagopal, PhD, co-founder and CEO of Esperto Medical
With this new funding, Esperto Medical is poised to advance its innovative RSM technology and potentially revolutionize blood pressure monitoring in both clinical and personal settings.
